Author:
Mikoshiba Naoko,Yamamoto-Mitani Noriko,Sato Kazuki,Asaoka Yoshinari,Ohki Takamasa,Ohata Misato,Miyashita Mitsunori
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (2011) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ). Accessed 11 Sep 2013
2. Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T (2006) Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. Jpn J Clin Oncol 36:768–774
3. Hyodo I, Shirao K, Doi T et al (2006) A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 36:410–417
4. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704
5. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299–305
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献